EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma

(UroToday.com) In this session, Dr. Thomas Powles provides an exploratory analysis of the DANUBE trial, with a focus on the outcomes of durvalumab (Durva) with or without tremelimumab (Treme) stratified by cisplatin eligibility and PD-L1 biomarker status in metastatic urothelial carcinoma (mUC). Dr. De Santis follows this discussion of the data and provides clinical context.